tetano
Editor, Senior Moderator
A A Pract
. 2020 May;14(7):e01236.
doi: 10.1213/XAA.0000000000001236.
Factor VIII and Functional Protein C Activity in Critically Ill Patients With Coronavirus Disease 2019: A Case Series
Ali Tabatabai[SUP] 1 [/SUP], Joseph Rabin[SUP] 2 [/SUP], Jay Menaker[SUP] 2 [/SUP], Ronson Madathil[SUP] 3 [/SUP], Samuel Galvagno[SUP] 4 [/SUP], Ashley Menne[SUP] 5 [/SUP], Jonathan H Chow[SUP] 4 [/SUP], Alison Grazioli[SUP] 6 [/SUP], Daniel Herr[SUP] 1 [/SUP], Kenichi Tanaka[SUP] 4 [/SUP], Thomas Scalea[SUP] 2 [/SUP], Michael Mazzeffi[SUP] 4 [/SUP]
Affiliations
Abstract
Critically ill patients with coronavirus disease 2019 (COVID-19) have been observed to be hypercoagulable, but the mechanisms for this remain poorly described. Factor VIII is a procoagulant factor that increases during inflammation and is cleaved by activated protein C. To our knowledge, there is only 1 prior study of factor VIII and functional protein C activity in critically ill patients with COVID-19. Here, we present a case series of 10 critically ill patients with COVID-19 who had severe elevations in factor VIII activity and low normal functional protein C activity, which may have contributed to hypercoagulability.
. 2020 May;14(7):e01236.
doi: 10.1213/XAA.0000000000001236.
Factor VIII and Functional Protein C Activity in Critically Ill Patients With Coronavirus Disease 2019: A Case Series
Ali Tabatabai[SUP] 1 [/SUP], Joseph Rabin[SUP] 2 [/SUP], Jay Menaker[SUP] 2 [/SUP], Ronson Madathil[SUP] 3 [/SUP], Samuel Galvagno[SUP] 4 [/SUP], Ashley Menne[SUP] 5 [/SUP], Jonathan H Chow[SUP] 4 [/SUP], Alison Grazioli[SUP] 6 [/SUP], Daniel Herr[SUP] 1 [/SUP], Kenichi Tanaka[SUP] 4 [/SUP], Thomas Scalea[SUP] 2 [/SUP], Michael Mazzeffi[SUP] 4 [/SUP]
Affiliations
- PMID: 32539272
- DOI: 10.1213/XAA.0000000000001236
Abstract
Critically ill patients with coronavirus disease 2019 (COVID-19) have been observed to be hypercoagulable, but the mechanisms for this remain poorly described. Factor VIII is a procoagulant factor that increases during inflammation and is cleaved by activated protein C. To our knowledge, there is only 1 prior study of factor VIII and functional protein C activity in critically ill patients with COVID-19. Here, we present a case series of 10 critically ill patients with COVID-19 who had severe elevations in factor VIII activity and low normal functional protein C activity, which may have contributed to hypercoagulability.